Literature DB >> 28842862

Neurotoxicity of the Cyanotoxin BMAA Through Axonal Degeneration and Intercellular Spreading.

Vanessa X Tan1,2, Benjamin Lassus2, Chai K Lim1, Philippe Tixador2, Josquin Courte2, Alban Bessede3, Gilles J Guillemin4, Jean-Michel Peyrin5.   

Abstract

β-Methylamino-L-alanine (BMAA) is implicated in neurodegeneration and neurotoxicity, particularly in ALS-Parkinson Dementia Complex. Neurotoxic properties of BMAA have been partly elucidated, while its transcellular spreading capacity has not been examined. Using reconstructed neuronal networks in microfluidic chips, separating neuronal cells into two subcompartments-(1) the proximal, containing first-order neuronal soma and dendrites, and (2) a distal compartment, containing either only axons originating from first-order neurons or second-order striatal neurons-creates a cortico-striatal network. Using this system, we investigated the toxicity and spreading of BMAA in murine primary neurons. We used a newly developed antibody to detect BMAA in cells. After treatment with 10 μM BMAA, the cyanotoxin was incorporated in first-degree neurons. We also observed a rapid trans-neuronal spread of BMAA to unexposed second-degree neurons in 48 h, followed by axonal degeneration, with limited somatic death. This in vitro study demonstrates BMAA axonal toxicity at sublethal concentrations and, for the first time, the transcellular spreading abilities of BMAA. This neuronal dying forward spread that could possibly be associated with progression of some neurodegenerative diseases especially amyotrophic lateral sclerosis.

Entities:  

Keywords:  Axonal degeneration; BMAA; Microfluidics; Neurotoxic; Spread

Mesh:

Substances:

Year:  2017        PMID: 28842862     DOI: 10.1007/s12640-017-9790-1

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  83 in total

Review 1.  Axonal self-destruction and neurodegeneration.

Authors:  Martin C Raff; Alan V Whitmore; John T Finn
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

2.  Endogenous prion protein conversion is required for prion-induced neuritic alterations and neuronal death.

Authors:  Sabrina Cronier; Julie Carimalo; Brigitte Schaeffer; Emilie Jaumain; Vincent Béringue; Marie-Christine Miquel; Hubert Laude; Jean-Michel Peyrin
Journal:  FASEB J       Date:  2012-06-01       Impact factor: 5.191

3.  Self-propagation and transmission of misfolded mutant SOD1: prion or prion-like phenomenon?

Authors:  Christian Münch; Anne Bertolotti
Journal:  Cell Cycle       Date:  2011-06-01       Impact factor: 4.534

4.  The seeds of neurodegeneration: prion-like spreading in ALS.

Authors:  Magdalini Polymenidou; Don W Cleveland
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

5.  Use of neurite outgrowth as an in vitro method of assessing neurotoxicity.

Authors:  E M Abdulla; I C Campbell
Journal:  Ann N Y Acad Sci       Date:  1993-05-28       Impact factor: 5.691

6.  TDP-43 regulates Drosophila neuromuscular junctions growth by modulating Futsch/MAP1B levels and synaptic microtubules organization.

Authors:  Vinay K Godena; Giulia Romano; Maurizio Romano; Chiara Appocher; Raffaella Klima; Emanuele Buratti; Francisco E Baralle; Fabian Feiguin
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

Review 7.  Does α-amino-β-methylaminopropionic acid (BMAA) play a role in neurodegeneration?

Authors:  Alexander S Chiu; Michelle M Gehringer; Jeffrey H Welch; Brett A Neilan
Journal:  Int J Environ Res Public Health       Date:  2011-09-16       Impact factor: 3.390

8.  Mapping amyotrophic lateral sclerosis lake risk factors across northern New England.

Authors:  Nathan Torbick; Sarah Hession; Elijah Stommel; Tracie Caller
Journal:  Int J Health Geogr       Date:  2014-01-02       Impact factor: 3.918

9.  Intracellular fibril formation, calcification, and enrichment of chaperones, cytoskeletal, and intermediate filament proteins in the adult hippocampus CA1 following neonatal exposure to the nonprotein amino acid BMAA.

Authors:  Oskar Karlsson; Anna-Lena Berg; Jörg Hanrieder; Gunnel Arnerup; Anna-Karin Lindström; Eva B Brittebo
Journal:  Arch Toxicol       Date:  2014-05-06       Impact factor: 5.153

10.  Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study.

Authors:  Ammar Al-Chalabi; Andrea Calvo; Adriano Chio; Shuna Colville; Cathy M Ellis; Orla Hardiman; Mark Heverin; Robin S Howard; Mark H B Huisman; Noa Keren; P Nigel Leigh; Letizia Mazzini; Gabriele Mora; Richard W Orrell; James Rooney; Kirsten M Scott; William J Scotton; Meinie Seelen; Christopher E Shaw; Katie S Sidle; Robert Swingler; Miho Tsuda; Jan H Veldink; Anne E Visser; Leonard H van den Berg; Neil Pearce
Journal:  Lancet Neurol       Date:  2014-10-07       Impact factor: 44.182

View more
  6 in total

Review 1.  BMAA and Neurodegenerative Illness.

Authors:  Paul Alan Cox; Richard M Kostrzewa; Gilles J Guillemin
Journal:  Neurotox Res       Date:  2017-05-24       Impact factor: 3.911

Review 2.  Neuropathological Mechanisms of β-N-Methylamino-L-Alanine (BMAA) with a Focus on Iron Overload and Ferroptosis.

Authors:  Hamed Kazemi Shariat Panahi; Mona Dehhaghi; Benjamin Heng; Darius J R Lane; Ashley I Bush; Gilles J Guillemin; Vanessa X Tan
Journal:  Neurotox Res       Date:  2022-01-13       Impact factor: 3.911

Review 3.  Parkinson's Disease: A Multisystem Disorder.

Authors:  Helena Nunes Costa; Ana Raquel Esteves; Nuno Empadinhas; Sandra Morais Cardoso
Journal:  Neurosci Bull       Date:  2022-08-22       Impact factor: 5.271

4.  Is Exposure to BMAA a Risk Factor for Neurodegenerative Diseases? A Response to a Critical Review of the BMAA Hypothesis.

Authors:  Dunlop Ra; Banack Sa; Bishop Sl; Metcalf Js; Murch Sj; Davis DA; Stommel Ew; Karlsson O; Brittebo Eb; Chatziefthimiou Ad; Tan Vx; Guillemin Gg; Cox Pa; Mash Dc; Bradley Wg
Journal:  Neurotox Res       Date:  2021-02-06       Impact factor: 3.911

5.  Quantification of Neurite Degeneration with Enhanced Accuracy and Efficiency in an In Vitro Model of Parkinson's Disease.

Authors:  Rachel T Clements; Lauren E Fuller; Kyle R Kraemer; Samantha A Radomski; Sarah Hunter-Chang; Wesley C Hall; Alborz A Kalantar; Bradley R Kraemer
Journal:  eNeuro       Date:  2022-03-18

Review 6.  Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies.

Authors:  Maria Inês Teixeira; Maria Helena Amaral; Paulo C Costa; Carla M Lopes; Dimitrios A Lamprou
Journal:  Pharmaceutics       Date:  2020-06-11       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.